NCT03884517 - Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

February 8, 2021

Study Completion Date

February 8, 2021

Conditions

Advanced Solid Cancer

Interventions

DRUG

BAT8003

Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Trial Locations (1)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou